GRCE
$4.45
Post-MarketAs of Mar 17, 8:00 PM UTC
Grace Therapeutics, Inc.
Historical Price
Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$4.45
Potential Upside
5%
Whystock Fair Value$4.67
Price
UndervaluedFair ValueOvervalued
Fundamentals
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$67.52M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.76
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-10.22%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
14.56
Recent News
This Grace Therapeutics Insider Increased Their Holding By 12% Last Year
Insiders were net buyers of Grace Therapeutics, Inc.'s ( NASDAQ:GRCE ) stock during the past year. That is, insiders...
We Think Grace Therapeutics (NASDAQ:GRCE) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Grace Therapeutics, Inc. (NASDAQ:GRCE) Is Expected To Breakeven In The Near Future
Grace Therapeutics, Inc. ( NASDAQ:GRCE ) is possibly approaching a major achievement in its business, so we would like...